Predictive cutoff point of admission N-terminal pro-B-type natriuretic peptide testing in the ED for prognosis of patients with acute heart failure

被引:9
作者
Golcuk, Yalcin [1 ]
Golcuk, Burcu [2 ]
Velibey, Yalcin [3 ]
Oray, Deniz [4 ]
Atilla, Ozge Duman [5 ]
Colak, Ayfer [6 ]
Kurtulmus, Yusuf [6 ]
Yildirim, Aydin [7 ]
Eren, Mehmet [7 ]
机构
[1] Bitlis State Hosp, Dept Emergency Med, Bitlis, Turkey
[2] Cigli State Hosp, Dept Clin Biochem, Izmir, Turkey
[3] Bitlis State Hosp, Dept Cardiol, Bitlis, Turkey
[4] Med Pk Hosp, Dept Emergency Med, Izmir, Turkey
[5] Tepecik Training & Res Hosp, Dept Emergency Med, Izmir, Turkey
[6] Tepecik Training & Res Hosp, Dept Biochem, Izmir, Turkey
[7] Training & Res Hosp, Siyami Ersek Thorac & Cardiovasc Surg Ctr, Dept Cardiol, Istanbul, Turkey
关键词
LEFT-VENTRICULAR DYSFUNCTION; POOLED ANALYSIS; DIAGNOSIS; DYSPNEA;
D O I
10.1016/j.ajem.2013.04.038
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: The main objective of this study was to determine a cutoff level of plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) that could successfully predict the short-and long-term prognosis of patients with acute heart failure at the time of admission to the emergency department. The results of our study are presented in context with previously published literature. We believe that the present study will be useful and salutary for the progress of literature. Methods: N-terminal pro-B-type natriuretic peptide plasma levels were obtained from 100 patients with shortness of breath and left ventricular dysfunction upon admission to the emergency department. All patients underwent follow-up evaluations 30 days and 1 year after admission. The end point was defined as all-cause mortality. Results: The mean age of the patients in this study was 70.8 +/- 11.6 years, and 51% were female. All-cause mortality at the 30-day and 1-year follow-up evaluations was 21.2% and 53.5%, respectively. We determined that the optimal NT-proBNP cutoff point for predicting 30-day mortality at the time of admission was 9152.4 pg/mL, with a 71.4% sensitivity and an 81.3% specificity (95% confidence interval, area under the curve: 0.726; P = .002). The optimal NT-proBNP cutoff point for predicting 1-year mortality at the time of admission was 3630.5 pg/mL, with an 83.0% sensitivity and a 52.2% specificity (95% confidence interval, area under the curve: 0.644; P = .014). Conclusion: Elevated NT-proBNP levels at the time of admission are a strong and independent predictor of all-cause mortality in patients with acute heart failure at 30 days and 1 year after admission. Furthermore, the optimal cutoff level of NT-proBNP used to predict 30-day and 1-year mortality had high sensitivity. (C) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:1191 / 1195
页数:5
相关论文
共 17 条
[1]   N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction [J].
Bayés-Genís, A ;
Santaló-Bel, M ;
Zapico-Muñiz, E ;
López, L ;
Cotes, C ;
Bellido, J ;
Leta, R ;
Casan, P ;
Ordóñez-Llanos, J .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) :301-308
[2]   Impact of history of heart failure on diagnostic and prognostic value of BNP: Results from the B-type Natriuretic Peptide for Acute Shortness of Breath Evaluation (BASEL) Study [J].
Boldanova, Tujana ;
Noveanu, Markus ;
Breidthardt, Tobias ;
Potocki, Mihael ;
Reichlin, Tobias ;
Taegtmeyer, Anne ;
Christ, Michael ;
Laule, Kirsten ;
Stelzig, Claudia ;
Mueller, Christian .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 142 (03) :265-272
[3]   The natriuretic peptides in heart failure: Diagnostic and therapeutic potentials [J].
Chen, HH ;
Burnett, JC .
PROCEEDINGS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, 1999, 111 (05) :406-416
[4]   B-type natriuretic peptide and amino terminal proBNP predict one-year mortality in short of breath patients independently of the baseline diagnosis of acute destabilized heart failure [J].
Gegenhuber, Alfons ;
Mueller, Thomas ;
Dieplinger, Benjamin ;
Poelz, Werner ;
Pacher, Richard ;
Haltmayer, Meinhard .
CLINICA CHIMICA ACTA, 2006, 370 (1-2) :174-179
[5]   Essential biochemistry and physiology of (NT-pro)BNP [J].
Hall, C .
EUROPEAN JOURNAL OF HEART FAILURE, 2004, 6 (03) :257-260
[6]   Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction [J].
Hammerer-Lercher, A ;
Neubauer, E ;
Müller, S ;
Pachinger, O ;
Puschendorf, B ;
Mair, J .
CLINICA CHIMICA ACTA, 2001, 310 (02) :193-197
[7]   EVOLUTION OF AMINO-TERMINAL PRO-B TYPE NATRIURETIC PEPTIDE TESTING IN HEART FAILURE [J].
Januzzi, James L. ;
Bayes-Genis, Antoni .
DRUG NEWS & PERSPECTIVES, 2009, 22 (05) :267-273
[8]   The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study [J].
Januzzi, JL ;
Camargo, CA ;
Anwaruddin, S ;
Baggish, AL ;
Chen, AA ;
Krauser, DG ;
Tung, R ;
Cameron, R ;
Nagurney, JT ;
Chae, CU ;
Lloyd-Jones, DM ;
Brown, DF ;
Foran-Melanson, S ;
Sluss, PM ;
Lee-Lewandrowski, EL ;
Lewandrowski, KB .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (08) :948-954
[9]   NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients [J].
Januzzi, JL ;
van Kimmenade, R ;
Lainchbury, J ;
Bayes-Genis, A ;
Ordonez-Llanos, J ;
Santalo-Bel, M ;
Pinto, YM ;
Richards, M .
EUROPEAN HEART JOURNAL, 2006, 27 (03) :330-337
[10]  
Levin ER, 1998, NEW ENGL J MED, V339, P321